AA
JBIO

ALPS Advisors’s Jade Biosciences JBIO Stock Holding History

ALPS Advisors’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-558
Closed -$577K – 969
2024
Q1 		$577K Buy
558
+23
+4% +$17.6K ﹤0.01% 574
2023
Q4 		$424K Sell
535
-48
-8% -$24.5K ﹤0.01% 636
2023
Q3 		$277K Buy
583
+60
+11% +$32.5K ﹤0.01% 900
2023
Q2 		$314K Buy
523
+60
+13% +$38.4K ﹤0.01% 839
2023
Q1 		$327K Sell
463
-14
-3% -$11.6K ﹤0.01% 771
2022
Q4 		$489K Buy
+477
New +$346K ﹤0.01% 597

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ALPS Advisors's JBIO Position: Q2 2024 in Review

ALPS Advisors sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 558 shares — an estimated $577K sold.

ALPS Advisors first reported a position in JBIO in Q4 2022 and held it in 6 quarters. The position peaked at $577K in Q1 2024. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

  • ALPS Advisors reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
  • ALPS Advisors sold 558 Jade Biosciences shares in Q2 2024, an estimated $577K.
  • ALPS Advisors first reported a position in Jade Biosciences in Q4 2022 and held it in 6 quarters.
  • ALPS Advisors's Jade Biosciences position peaked at $577K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on ALPS Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.